Genome Editing Global Market-Forecast to 2022

Publishing Date : September, 2016
Report Code : HCBT0110
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Ever since the establishment of the genetic basis of life, researchers have tried to manipulate genes in plants and animals to improve traits. There has been a continuous evolution of gene modification technique starting from restriction endonucleases, transgenic breeding, RNAi technologies to the current engineered endonucleases. Over the last several decades, technologies for identification, isolation, sequencing, replication and integration of desired genes in target organisms have transformed tremendously and emerged as one of the exciting and significant areas of scientific endeavour.

The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc. Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software.  Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.

This report studies the genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at a CAGR of 31.1%. Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.

Geographically, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America dominated the genome editing market with the largest share which is driven by factors such as increasing awareness of technology, proximity of companies, and early adoption of latest treatments. The Asian market is expected to occupy second place due increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed regulatory environment. The European market is expected to be third largest market, growing at a lower rate mainly due to the stringent regulatory environment and slow growth due to the economic crisis.

The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN & DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET OVERVIEW
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
    • 3.4     MARKET DYNAMICS
      • 3.4.1     DRIVERS AND OPPORTUNITIES
        • 3.4.1.1     INCREASED R&D EXPENDITURE AND GROWTH OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES.
        • 3.4.1.2     INVESTMENTS FROM BOTH PUBLIC AND PRIVATE SECTORS FOR GENE-EDITING TECHNOLOGY
        • 3.4.1.3     TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING AND GENE EDITING TECHNOLOGIES
        • 3.4.1.4     NON-TRANSGENIC BREEDING TECHNOLOGIES AND GENE-EDITED PLANTS NOT LABELLED AS GMO IN MANY COUNTRIES
        • 3.4.1.5     IMPROVEMENT IN DRUG DISCOVERY PROCESS
        • 3.4.1.6     VARIED APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT, PLANT ENGINEERING, IMPROVEMENT IN ANIMAL TRAITS, THERAPEUTICS
        • 3.4.1.7     PRECISION MEDICINE AND NEW THERAPEUTICS FOR GENETIC AND OTHER DISORDERS
      • 3.4.2     RESTRAINTS AND THREATS
        • 3.4.2.1     STRINGENT REGULATORY FRAMEWORKS
        • 3.4.2.2     ETHICAL ISSUES CONCERNING EDITING HUMAN EMBRYO AND ADVERSE PUBLIC PERCEPTION
        • 3.4.2.3     UNAVAILABILITY OF GENE-EDITING BASED THERAPEUTIC PRODUCT IN THE MARKET AND LESS GEOGRAPHIC PENETRATION DUE TO UNCERTAIN REGULATIONS
        • 3.4.2.4     PATENT DISPUTE ASSOCIATED WITH CRISPR/CAS
        • 3.4.2.5     OFF-TARGET EFFECTS OF CRISPR/CAS9 GENOME EDITING TECHNOLOGY
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     BARGAINING POWER OF SUPPLIERS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.6     REGULATORY AFFAIRS
      • 3.6.1     NORTH AMERICA
      • 3.6.2     EUROPE
      • 3.6.3     CHINA
      • 3.6.4     JAPAN
      • 3.6.5     INDIA
      • 3.6.6     LATIN AMERICA
    • 3.7     PATENT ANALYSIS
    • 3.8     FUNDING SCENARIO
    • 3.9     COLLABORATION, JOINT VENTURE, PARTNERSHIP, AGREEMENT
    • 3.1     MARKET SHARE ANALYSIS
  • 4     GENOME EDITING GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     ZINC FINGER NUCLEASE (ZFN)
    • 4.3     TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALEN)
    • 4.4     CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR/CAS9)
      • 4.4.1     WT CRISPR/CAS9
      • 4.4.2     CRISPR/CAS9 NICKASE
      • 4.4.3     CRISPR DCAS9
    • 4.5     OTHERS
      • 4.5.1     RECOMBINANT ADENO-ASSOCIATED VIRUS (R AAV)
      • 4.5.2     PIGGYBAC TRANSPOSASE AND SLEEPING BEAUTY TRANSPOSON
      • 4.5.3     ARCUS (HOMING ENDONUCLEASE) AND MEGATAL
      • 4.5.4     TARGATT AND RAPID TRAIT DEVELOPMENT SYSTEM (RTDS)
  • 5     GENOME EDITING GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     BASIC RESEARCH
      • 5.2.1     TRANSCRIPTION ACTIVATION/REPRESSION
      • 5.2.2     GENOMIC SCREENING
      • 5.2.3     GENOMIC VISUALIZATION
    • 5.3     PLANT BIOTECHNOLOGY/AGRICULTURE
    • 5.4     ANIMAL BIOTECHNOLOGY
      • 5.4.1     ANIMAL HEALTH
      • 5.4.2     LIVESTOCK
      • 5.4.3     OTHER
    • 5.5     DRUG DISCOVERY AND DEVELOPMENT
      • 5.5.1     PRE-CLINICAL
      • 5.5.2     CLINICAL
  • 6     GENOME EDITING GLOBAL MARKET, BY PRODUCTS AND SERVICES
    • 6.1     INTRODUCTION
    • 6.2     REAGENTS, ENZYMES AND CONSUMABLES
      • 6.2.1     GENOME EDITING TOOLS AND KITS
      • 6.2.2     DELIVERY TOOLS
      • 6.2.3     OTHER REAGENTS, ENZYMES AND CONSUMABLES
    • 6.3     CELL LINES AND ANIMAL MODELS
    • 6.4     GENOME EDITING SERVICES
    • 6.5     INSTRUMENTS
    • 6.6     SOFTWARE
  • 7     GENOME EDITING GLOBAL MARKET, BY END USERS
    • 7.1     INTRODUCTION
    • 7.2     ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
    • 7.3     PLANT BIOTECHNOLOGY COMPANIES
    • 7.4     PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 7.5     OTHERS
      • 7.5.1     ANIMAL BIOTECHNOLOGY
      • 7.5.2     CONTRACT RESEARCH ORGANIZATIONS (CRO)
  • 8     GENOME EDITING GLOBAL MARKET, BY REGION
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
    • 8.3     EUROPE
    • 8.4     ASIA-PACIFIC
      • 8.4.1     CHINA
      • 8.4.2     JAPAN
      • 8.4.3     INDIA
    • 8.5     REST OF THE WORLD (ROW)
      • 8.5.1     LATIN AMERICA
      • 8.5.2     MIDDLE EAST
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
      • 9.1.1     LICENSING AGREEMENT AND OTHERS AS A MAJOR GROWTH STRATEGY OF MARKET PLAYERS
    • 9.2     LICENSING AGREEMENT
    • 9.3     OTHER DEVELOPMENTS
    • 9.4     AGREEMENT/COLLABORATION/PARTNERSHIP/JOINT VENTURE
    • 9.5     APPROVAL
    • 9.6     NEW PRODUCT LAUNCH
    • 9.7     ACQUISITIONS
  • 10     MAJOR COMPANIES
    • 10.1     APPLIED STEMCELL INC.
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     CELLECTIS S.A.
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     GENSCRIPT BIOTECH CORPORATION
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     HORIZON DISCOVERY GROUP, PLC
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     MERCK KGAA
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     ORIGENE TECHNOLOGIES, INC.
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     SANGAMO BIOSCIENCES
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     SYSTEM BIOSCIENCES
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     THERMO FISHER SCIENTIFIC INC.
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.1     TRANSPOSAGEN
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 2     GENOME EDITING GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
      • TABLE 3     ZFN GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 4     TALEN GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 5     CRISPR GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 6     OTHERS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 7     GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 8     BASIC RESEARCH GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 9     PLANT BIOTECHNOLOGY/AGRICULTURE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 10     ANIMAL BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 11     DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 12     DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 13     PRE-CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 14     CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 15     GENOME EDITING GLOBAL MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
      • TABLE 16     REAGENTS, ENZYMES AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 17     CELL LINES AND ANIMAL MODELS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 18     GENOME EDITING SERVICES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 19     INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 20     GENOME EDITING SOFTWARE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 21     GENOME EDITING GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 22     ACADEMIC AND GOVERNENMENT INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 23     PLANT BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • TABLE 24     PHARMACEUTICAL AND BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 25     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 26     GENOME EDITING, GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 27     NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 28     NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 29     NORTH AMERICAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 30     NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
      • TABLE 31     NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 32     EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 33     EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 34     EUROPEAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 35     EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
      • TABLE 36     EUROPE GENOME EDITING MARKET REVENUE, BY END USERS, (2014-2022) ($MN)
      • TABLE 37     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 38     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 39     ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 40     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
      • TABLE 41     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 42     ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
      • TABLE 43     ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
      • TABLE 44     ROW DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 45     ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
      • TABLE 46     ROW GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 47     LICENSING AGREEMENT (2015-2016)
      • TABLE 48     OTHER DEVELOPMENTS (2015-2016)
      • TABLE 49     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2015-2016)
      • TABLE 50     APPROVALS (2015-2016)
      • TABLE 51     NEW PRODUCT LAUNCH (2015-16)
      • TABLE 52     ACQUISITIONS (2015)
      • TABLE 53     CELLECTIS S.A.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 54     CELECTIS S.A.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 55     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 56     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 57     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 58     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 59     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 60     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 61     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 62     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 63     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 64     SANGAMO BIOSCIENCES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 65     SANGAMO BIOSCIENCES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 66     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 67     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 68     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: GENOME EDITING GLOBAL MARKET
      • FIGURE 3     GENOME EDITING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     GENOME EDITING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     GENOME EDITING GLOBAL MARKET: MARKET CRACKDOWN & DATA TRIANGULATION
      • FIGURE 6     GENOME EDITING GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     GENOME EDITING GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     GENOME EDITING GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2016)
      • FIGURE 10     APPLICATIONS WISE FUNDING ($MN) IN GENOME EDITING MARKET (SINCE-2015)
      • FIGURE 11     ADOPTION OF DIFFERENT GENOME EDITING TECHNOLOGIES BY DIFFERENT COMPANIES
      • FIGURE 12     SELECTED DEALS IN GENOME EDITING MARKET (SINCE-2015)
      • FIGURE 13     GLOBAL GENOME EDITING MARKET SHARE ANALYSIS BY KEY PLAYERS (2015) (%)
      • FIGURE 14     GLOBAL GENOME EDITING MARKET REVENUE BY TECHNOLOGY, (2015 V’S 2022) ($MN)
      • FIGURE 15     GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 16     GLOBAL GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
      • FIGURE 17     GENOME EDITING GLOBAL MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
      • FIGURE 18     GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • FIGURE 19     NORTH AMERICAN GENOME EDITING MARKET REVENUE BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 20     NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 21     NORTH AMERICAN GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICE, (2015 V’S 2022) ($MN)
      • FIGURE 22     NORTH AMERICAN GENOME EDITING MARKET REVENUE BY END USERS, (2015 V’S 2022) ($MN)
      • FIGURE 23     EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 24     EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 25     EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
      • FIGURE 26     EUROPEAN GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
      • FIGURE 27     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2015 V’S 2022) ($MN)
      • FIGURE 28     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 29     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
      • FIGURE 30     ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
      • FIGURE 31     ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 32     ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 33     ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
      • FIGURE 34     ROW GENOME EDITING MARKET REVENUE, BY END USER, (2015 V'S 2022) ($MN)
      • FIGURE 35     KEY GROWTH STRATEGIES (2015-2016)
      • FIGURE 36     SWOT: APPLIED STEMCELL INC.
      • FIGURE 37     SWOT: CELLECTIS S.A.
      • FIGURE 38     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 39     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 40     SWOT: MERCK KGAA
      • FIGURE 41     SWOT: ORIGENE TECHNOLOGIES
      • FIGURE 42     SWOT: SANGAMO BIOSCIENCES
      • FIGURE 43     SWOT: SYSTEM BIOSCIENCES
      • FIGURE 44     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 45     SWOT: TRANSPOSAGEN

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABCAM
      • 2     ADDGENE
      • 3     AGILENT TECHNOLOGIES
      • 4     APPLIED BIOLOGICAL MATERIALS (ABM)
      • 5     AXOL BIOSCIENCE LTD
      • 6     BIO-RAD LABORATORIES
      • 7     CARIBOU BIOSCIENCES
      • 8     CHARLES RIVER LABORATORIES
      • 9     CIBUS
      • 10     CRISPR THERAPEUTICS
      • 11     DESKTOP GENETICS
      • 12     DISCOVERY GENOMICS
      • 13     EDITAS MEDICINE
      • 14     EISAI
      • 15     ERS GENOMICS
      • 16     GE HEALTHCARE
      • 17     GENECOPOEIA
      • 18     GENUS INC
      • 19     HOMOLOGY MEDICINES
      • 20     ILLUMINA
      • 21     INTEGRATED DNA TECHNOLOGIES (IDT)
      • 22     INTELLIA THERAPEUTICS
      • 23     LONZA
      • 24     NEW ENGLAND BIOLABS (NEB)
      • 25     PACIFIC BIOSCIENCE
      • 26     PRECISION BIOSCIENCES
      • 27     PROTEONIC B.V.
      • 28     RECOMBINETICS
      • 29     SHIRE PLC
      • 30     STEMGENT, INC
      • 31     SYNGENTA
      • 32     TAKARA BIO
      • 33     TARGETGENE BIOTECHNOLOGIES
      • 34     TIDE
      • 35     TOOLGEN
      • 36     TRANSGENIC
      • 37     VIRAVECS LABS